Fenwick Represents Shockwave Medical in Acquisition by Johnson & Johnson

Fenwick represented Shockwave Medical, Inc. (Nasdaq: SWAV), a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease, in its acquisition by Johnson & Johnson (NYSE: JNJ).

Under the terms of the agreement, Johnson & Johnson acquired all outstanding shares of Shockwave for $335 per share, for an aggregate enterprise value of approximately $13.1 billion. More information can be obtained from Johnson & Johnson’s announcement.

The Fenwick transaction team included corporate partners Doug Cogen, Bomi Lee, Ran Ben-Tzur and Jen Hitchcock and associates Chris Gorman, Jiarui Li, Liz Malmen, Christina Scully, Christian Choi, Tempestt Edward, Beth Clarke, Kaylee Johnson, Warren Pugash and Sammi Chen; technology transactions partner Stefano Quintini and associates Jennifer Yoon, Kehl Sink, Phillip Yin and Rob Ferrari; executive compensation partner Matt Cantor and associates Jonathan Stephenson and Elizabeth Fu; antitrust partner Tom Ensign and associate Elizabeth Suarez; patent litigation partner Jeff Oelke and associate Jon McMichael; healthcare regulatory partner Jennifer Yoo; and tax partner Adam Halpern and associate Einav Axler.